Breast Cancer Cell Model for PKC alpha over-expression and Tamoxifen resistance
Technology description
Clinically relevant breast cancer cell lines that can be used to test and validate novel therapeutics for tamoxifen resistant breast cancer.
- UIC researchers have developed several clinically relevant breast cancer cell lines in order to investigate the efficacy of novel anti-tumor drugs. The T47D:A18/PKCa cell line was engineered to exogenously overexpress Protein Kinase C alpha (PKCα) which rendered it resistant to tamoxifen. A control cell line has also been generated for the PKCα expression.
- The cell lines have been used in in-vitro studies as well as to generate in-vivo mouse xenograft tumor models.
- The culture conditions, morphology and growth behavior of the cell lines are well characterized and they have been authenticated using short tandem repeat (STR) and ATCC analysis.
- These cell lines have been designed to test and validate novel therapeutics for tamoxifen resistant breast cancer. They are co-owned by UIC and Northwestern University.
Application area
The (T47D:A18/PKCa) with exogenous PKCα over-expression along with the control cell line T47D:A:18/neo can be used:
To study the biology of clinically relevant breast cancer
To examine effects of novel drugs to treat tamoxifen resistant breast cancer
Advantages
- These are cells with a stable and robust expression of PKCα.
- The PKCα over-expression renders them tamoxifen resistant which is a clinically relevant cell model
- They are ready to use for drug discovery and validation studies
March 15, 2016
B5, No.1600, North Guoquan Rd, Yangpu, Shanghai
info@yintrust.com
021-65679356
Premium